title: Management of posttransplant lymphoproliferative disorders following solid organ transplant: an update.
abstract: Development of secondary malignancies is a well-known complication of solid organ transplant, with skin cancer and lymphoproliferative disorders being most frequently observed. Posttransplant lymphoproliferative disorders, caused by diminished immune surveillance, represent a broad spectrum of pathological and clinical disorders, ranging from benign conditions to very aggressive lymphomas. Here we review treatment options for adult patients experiencing posttransplant lymphoproliferative disorders following solid organ transplant.
authors.affiliation: Department of Hematology, University Hospitals Leuven, Leuven, Belgium. daan.dierickx@uzleuven.be
authors.forename: Daan
authors.initials: D
authors.lastname: Dierickx
authors.forename: Thomas
authors.initials: T
authors.lastname: Tousseyn
authors.forename: Christiane
authors.initials: C
authors.lastname: De Wolf-Peeters
authors.forename: Jacques
authors.initials: J
authors.lastname: Pirenne
authors.forename: Gregor
authors.initials: G
authors.lastname: Verhoef
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy / Q000209:etiology / Q000821:virology; D004854:Herpesvirus 4, Human / Q000187:drug effects; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000628:therapy*; D016377:Organ Transplantation / Q000009:adverse effects* / Q000379:methods; D011183:Postoperative Complications / Q000209:etiology / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods
chemical_list: D000998:Antiviral Agents